Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Skinvisible (SKVI) EBITDA (2016 - 2025)

Historic EBITDA for Skinvisible (SKVI) over the last 17 years, with Q3 2025 value amounting to -$106057.0.

  • Skinvisible's EBITDA rose 1513.34% to -$106057.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$580889.0, marking a year-over-year decrease of 1014.54%. This contributed to the annual value of -$589589.0 for FY2024, which is 2023.23% down from last year.
  • Latest data reveals that Skinvisible reported EBITDA of -$106057.0 as of Q3 2025, which was up 1513.34% from -$136237.0 recorded in Q2 2025.
  • Over the past 5 years, Skinvisible's EBITDA peaked at $159520.0 during Q2 2021, and registered a low of -$198743.0 during Q4 2024.
  • Its 5-year average for EBITDA is -$79603.3, with a median of -$117716.0 in 2022.
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 181337.05% in 2021, then plummeted by 151934.29% in 2022.
  • Quarter analysis of 5 years shows Skinvisible's EBITDA stood at $147540.0 in 2021, then crashed by 179.79% to -$117716.0 in 2022, then decreased by 15.99% to -$136538.0 in 2023, then tumbled by 45.56% to -$198743.0 in 2024, then soared by 46.64% to -$106057.0 in 2025.
  • Its EBITDA was -$106057.0 in Q3 2025, compared to -$136237.0 in Q2 2025 and -$139852.0 in Q1 2025.